1. © Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Emerging Pulmonary Drug Delivery Technologies Markets Technological Innovation to Drastically Change Market Landscape “The development of path breaking, non-invasive, pulmonary drug delivery technologies such as chlorofluorocarbons (CFC)-free metered dose inhalers (MDI), dry powder inhalers (DPI), and liquid-based inhalers (LBIs) invites many companies to enter the lucrative market, intensifying competition.” Pharmaceutical Biotech Analyst Team Frost & Sullivan

2. © Copyright 2002 Frost & Sullivan. All Rights Reserved. Frost & Sullivan provides: Detailed insights into recent developments and trends Drivers, restraints, challenges, and strategic recommendations Analyst insights on ‘hot topics’ and emerging applications in the market Market sizing and competitive analysis Market forecasts and opportunity analysis Quarterly assessments End user analysis within each report Key Features

3. © Copyright 2002 Frost & Sullivan. All Rights Reserved. Coverage: The United States Proven methodology encompassing extensive primary and secondary data and research Focused information and strategies that cover business and technology issues Credible data and analysis highlighting industry dynamics Winning strategies to help you create precise business plans What We Offer

4. © Copyright 2002 Frost & Sullivan. All Rights Reserved. Current Market Participants Find out how you compare to the competition Assess current and future drivers and restraints Determine and exploit new market share opportunities New Entrants Analyze challenges associated with the industry Calculate time scales for strategy implementation Position yourself to capitalize on the market’s unmet needs Investment Community Analyze long-term strategies of companies Determine which participants will outperform the competition Assess attractiveness of investing in the market Who Will Benefit?

5. © Copyright 2002 Frost & Sullivan. All Rights Reserved. 3M Drug Delivery Systems Abbott Laboratories (Ross products division) Acrux Ltd. Adaptive Aerosol Delivery Systems/ Profile Therapeutics Ltd. Aerogen, Inc. Aeropharm Technology, Inc. Alkermes, Inc. Aradigm Corp. AstraZeneca Pharmaceuticals LP Aventis Pharmaceuticals, Inc. Battelle Medical Products Bespak Plc - Drug Delivery Technologies BioSante Pharmaceuticals, Inc. Boehringer Ingelheim Pharmaceuticals, Inc. Chiesi Farmaceutici SpA Chiron Corp. Direct-Haler A/S Elan Corp., Plc - Drug Delivery Systems Eli Lilly and Co. Emisphere Technologies, Inc. Enzon, Inc. Exhale Therapeutics, Inc. FDA/Center for Drug Evaluation & Research (HFD–7) First Principals, Inc. Key Market Participants

6. © Copyright 2002 Frost & Sullivan. All Rights Reserved. Generex Biotechnology Corp. GlaxoSmithKline, Inc. Inhale Therapeutic Systems, Inc. LTS LOHMANN Therapie-Systeme AG MicroDose Technologies, Inc. Muro Pharmaceutical, Inc. Nobex Corp. Novo Nordisk A/S Oriel Therapeutics, Inc. Ortho McNeil Pharmaceutical, Inc. Pfizer, Inc. Pharmacia Corp. Profile Therapeutics Plc Respirics, Inc. Schering Plough Corp. Sepracor, Inc. Sheffield Pharmaceuticals, Inc. SkyePharma Plc Unimed Pharmaceuticals, Inc./ Solvay Pharmaceuticals, Inc. Vectura Delivery Devices Ltd. Viasys Healthcare, Inc. ViroPharma, Inc. Key Market Participants

7. © Copyright 2002 Frost & Sullivan. All Rights Reserved. Call toll free 877 G O F ROST (877.463.7876) Fax toll free 888.690.3329 E-mail myfrost@frost.com Visit www.frost.com For More Information